A New Opportunity forInvestors + Partners
Liver cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer deaths worldwide with more than 7oo,ooo new cases and 600,000 deaths each year*. Diagnosis is often late, when the patient’s liver is failing, which limits treatment options, care is costly and mortality rates are high.
Matrix-Bio is redefining liver cancer diagnostics through metabolite profiling, a highly accurate means of detecting early stage liver cancer, predicting recurrence and monitoring treatment effectiveness. We have developed a blood serum-based test for early detection of hepatocellular carcinoma (HCC), the most common primary liver malignancy, for monitoring patients with chronic hepatitis B and C, who are at high risk of developing liver cirrhosis and ultimately HCC. In early studies, Matrix-Bio’s HCC test has demonstrated 95% accuracy, which facilitates early diagnosis when there are more treatment options.
High Unmet Need
Effective surveillance for HCC is an important unmet need for monitoring and managing patients with cirrhosis and at high risk of HCC. The American Association for the Study of Liver Disease recommends at least one annual screening for HCC in patients with cirrhosis using imaging with liver ultrasound, triphasic CT scan, or gadolinium enhance MRI.
The two tests most commonly used for HCC surveillance in chronic hepatitis B and C patients are alpha-fetoprotein and liver ultrasound. Alpha-fetoprotein has poor sensitivity and specificity, particularly for early detection of HCC. Liver ultrasound is significantly limited by technician skill and the ultrasound equipment. Some centers also routinely use imaging modalities such as magnetic resonance imaging (MRI) for surveillance due to the shortcomings of these tests, but MRI is very expensive for routine surveillance.
Sophisticated technology, simple to implement
VeraMarker™, Matrix-Bio’s advanced metabolite profiling technology platform, identifies the unique metabolite signature of cancer cells in blood serum samples in real time, with more specificity and sensitivity than current diagnostic tests. Our HCC test offers a more accurate option for early detection of HCC that in turn can support significantly improved patient outcomes.
Significant cost savings are possible with a high accuracy HCC test by reducing the utilization of high-cost imaging studies such as CT, MRI, and PET scans that are used for surveillance or to follow up false positive results from other tests. Because Matrix-Bio’s HCC test is blood-serum based, it will be easy to implement, offers greater immediacy and is more acceptable to patients.
More good news: our IP position is strong. Matrix-Bio two issued patents and 11 patent applications pending.
Matrix-Bio is seeking support from investors and strategic partners to validate our VeraMarker™ liver cancer screening test and bring this important technology to the market. Email Matrix-Bio CEO Eric Beier to start a conversation.
* American Cancer Society